Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of Quality of Life, Efficacy, and Safety Following Administration of Advanced Immuno-Oncology Agents Versus Conventional Immunotherapies in Patients With Relapsed/Refractory Multiple Myeloma

NCT07051850 is registered in ClinicalTrials.gov with Sung-Soo Park as lead sponsor.

NCT NCT07051850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07051850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of Quality of Life, Efficacy, and Safety Following Administration of Advanced Immuno-Oncology Agents Versus Conventional Immunotherapies in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Sung-Soo Park
Phase
Observational
Overall status
Recruiting
Start date
July 14, 2025
Completion date
December 31, 2025
Enrollment
174 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma (mm), multiple myeloma, relapsed